Zonglang Zhou1,2, Jun Xie3, Sihan Ma4, Xian Luo3, Jiajing Liu3, Shengyu Wang3, Yuqiang Chen1,2, Jianghua Yan3, Fanghong Luo3. 1. The 174th Clinic College of People's Liberation Army, Anhui Medical University, Hefei 230031, China. 2. The 73rd Army Hospital of the Chinese People's Liberation Army, Xiamen 361003, China. 3. School of Medicine, Xiamen University, Xiamen 361005, China. 4. College of Energy, Xiamen University, Xiamen 361005, China.
Abstract
High-efficiency nanotheranostic agents with multimodal imaging guidance have attracted considerable interest in the field of cancer therapy. Herein, novel silver-decorated bismuth-based heterostructured polyvinyl pyrrolidone nanoparticles (NPs) with good biocompatibility (Bi-Ag@PVP NPs) were synthesized for accurate theranostic treatment, which can integrate computed tomography (CT)/photoacoustic (PA) imaging and photodynamic therapy/photothermal therapy (PDT/PTT) into one platform. The Bi-Ag@PVP NPs can enhance light absorption and achieve a better photothermal effect than bismuth NPs. Moreover, after irradiation under an 808 nm laser, the Bi-Ag@PVP NPs can efficiently induce the generation of reactive oxygen species (ROS), thereby synergizing PDT/PTT to exert an efficient tumor ablation effect both in vitro and in vivo. Furthermore, Bi-Ag@PVP NPs can also be employed to perform enhanced CT/PA imaging because of their high X-ray absorption attenuation and enhanced photothermal conversion. Thus, they can be utilized as a highly effective CT/PA imaging-guided nanotheranostic agent. In addition, an excellent antibacterial effect was achieved. After irradiation under an 808 nm laser, the Bi-Ag@PVP NPs can destroy the integrity of Escherichia coli, thereby inhibiting E. coli growth, which can minimize the risk of infection during cancer therapy. In conclusion, our study provides a novel nanotheranostic platform that can achieve CT/PA-guided PDT/PTT synergistic therapy and have potential antibacterial properties. Thus, this work provides an effective strategy for further broad clinical application prospects.
High-efficiency nanotheranostic agents with multimodal imaging guidance have attracted considerable interest in the field of n class="Gene">pan class="Disease">cancer therapy. Herein, novel ne">pan>n class="Chemical">silver-decorated bismuth-based heterostructured polyvinyl pyrrolidone nanoparticles (NPs) with good biocompatibility (Bi-Ag@PVP NPs) were synthesized for accurate theranostic treatment, which can integrate computed tomography (CT)/photoacoustic (PA) imaging and photodynamic therapy/photothermal therapy (PDT/PTT) into one platform. The Bi-Ag@PVP NPs can enhance light absorption and achieve a better photothermal effect than bismuth NPs. Moreover, after irradiation under an 808 nm laser, the Bi-Ag@PVP NPs can efficiently induce the generation of reactive oxygen species (ROS), thereby synergizing PDT/PTT to exert an efficient tumor ablation effect both in vitro and in vivo. Furthermore, Bi-Ag@PVP NPs can also be employed to perform enhanced CT/PA imaging because of their high X-ray absorption attenuation and enhanced photothermal conversion. Thus, they can be utilized as a highly effective CT/PA imaging-guided nanotheranostic agent. In addition, an excellent antibacterial effect was achieved. After irradiation under an 808 nm laser, the Bi-Ag@PVP NPs can destroy the integrity of Escherichia coli, thereby inhibiting E. coli growth, which can minimize the risk of infection during cancer therapy. In conclusion, our study provides a novel nanotheranostic platform that can achieve CT/PA-guided PDT/PTT synergistic therapy and have potential antibacterial properties. Thus, this work provides an effective strategy for further broad clinical application prospects.
As a highly malignant
disease, n class="Disease">cancern> significantly threatens the
health of human beings around the world. Although continuous efforts
have been made by researchers to improve cancer treatment, the annual
number of deaths from cancer remains high.[1−3] Cancer treatment
methods mainly include phototherapy, chemotherapy, radiotherapy, surgery,
targeted therapy, and immunotherapy.[4−11] Among these therapeutic approaches, phototherapy has attracted considerable
interest from researchers due to its high specificity, low invasiveness,
and negligible side effects.[12−16] Phototherapeutic strategies include photodynamic therapy (PDT) and
photothermal therapy (PTT). Due to various breakthroughs and its unique
advantages, such as negligible invasiveness and spatiotemporal selectivity,
PDT has been widely used for cancer therapy.[17] PDT relies on photosensitizers. When the laser irradiates the photosensitizer,
it can absorb laser energy to produce reactive oxygen species (ROS),
which can cause tumor cell damage, necrosis, and apoptosis.[18,19] However, traditional photosensitizers, such as chlorin e6 (Ce6)
and photofrin, have some drawbacks, including poor photostabilities
and visible light irradiation with low tissue penetration. Furthermore,
they exhibit relatively insufficient antitumor effects because PDT
can aggravate the hypoxic environment inside the tumor, resulting
in an insufficient generation of ROS.[20] Therefore, the investigation of photosensitizers with more effective
antitumor effects, good photostabilities, and the usage of near-infrared
(NIR) excitation is of great significance.
As another phototherapy
strategy, PTT has attracted broad interest
from researchers due to its high selen class="Gene">ctivity and minimal invasiveness,[21] which requires photothermal agents (PTAs) to
convert light energy into heat to kill n class="Disease">tumor cells. Ideal PTAs can
efficiently convert light into heat; thus, good light energy conversion
is a prerequisite of PTAs.[22] At present,
pan class="Chemical">indocyanine green (ICG) is the only PTA approved for clinical use.[23] However, the insufficient photothermal conversion
efficiency and poor solubility limit its therapeutic effect on malignant
tumors. Hence, it is necessary to develop an effective PTA with a
high luminous thermal efficiency.
pan class="Chemical">Bismuth nanomaterials with
low cost, good biocompatibility, and
high atomic numbers have attracted considerable interest and can integrate
PDT and PTT, overcoming their drawbacks described above. Recently,
the development of nanomaterials with synergistic tumor ablation has
attracted considerable interest of researchers. For instance, Zhang
et al. have developed pH-responsive Ce6-conjugated gold nanorods (Ce6-PEG-AuNRs),
which can achieve fluorescence-guided PTT/PDT ablation of tumors.[24] Song et al. synthesized a Bi2Se3@HA-doped PPy/ZnPc nanodish complex using bismuth as a raw
material, which could simultaneously exert photothermal and photodynamic
effects and had an excellent tumor-growth inhibition ratio (96.4%).[25] Liu et al. reported a novel Bi-based nanocomposite
(UCNP@NBOF-FePc-PFA) that could not only enable the upconversion luminescence/CT
bioimaging of living beings but also be applied for photothermal/photodynamic/radio
synergistic tumor ablation.[26] These materials
have great antitumor effects and potential applications in biomedicine.
However, there have been few investigations on high-content bismuth
nanomaterials. It is worthwhile to develop biomedical theranostic
applications of high-content bismuth nanomaterials. As is well known,
the decoration of engineering structures can improve their photonic
absorption properties; thus, the engineering decoration of nanomaterials
is significant for enhancing photonic properties.
Herein, pan class="Chemical">silver-decorated
bismuth-based heterostructured polyvinyl
pyrrolidone nanoparticles (Bi-Ag@PVP NPs) with nanoheterostructures
were facilely synthesized via a two-step method. After modification
of PVP, the Bi-Ag@PVP NPs possessed low cytotoxicity and caused little
damage to normal organs. Notably, under 808 nm laser irradiation,
the Bi-Ag@PVP NPs exhibited a better photothermal effect than single
bismuth NPs (Bi@PVP NPs) in vivo and in vitro. Importantly, the Bi-Ag@PVP
NPs could employ NIR to generate ROS, thereby synergizing PDT and
PTT to ablate tumor cells, achieving an enhanced therapeutic effect.
Meanwhile, the Bi-Ag@PVP NPs also possessed computed tomography (CT)
and photoacoustic (PA) dual-modal imaging properties, enhancing the
CT and PA contrast of tumor sites. Interestingly, the Bi-Ag@PVP NPs
could be effectively used to kill Escherichia coli, indicating that the Bi-Ag@PVP NPs had an excellent antibacterial
function and could be used to avoid bacterial infections during cancer
therapy. In brief, the multifunctional Bi-Ag@PVP NPs could achieve
an accurate theranostic effect; thus, they have a bright future in
cancer therapy.
Experimental
Fabrication of Bi@PVP NPs
First,
1 mmol of Bi(NO3)3·5H2O was
dispersed in 10 mL of pan class="Chemical">HNO3 (1 M); then, the solution was
added to 50 mL of pan class="Chemical">ethylene glycol containing 0.8 g of PVP (Mw = 10000) and 0.2 g of NaOH. After vigorous
mixing and ultrasonic treatment for 10 min, the reaction system was
transferred to a 100 mL reaction vessel and heated for 3 h at 150
°C. When the reaction system cooled to room temperature, the
samples were collected by centrifugation (8000 rpm, 5 min), washed
with double distilled water (ddH2O) and alcohol to remove
the residue, and finally frozen and dried to obtain Bi@PVP NPs.
Synthesis of Bi-Ag@PVP NPs
First,
25 mg of the above-synthesized Bi@pan class="Chemical">PVP NPs was scattered in 20 mL of
pan class="Chemical">ddH2O. Subsequently, 5 mL of bovine serum album (BSA) solution
(4 mg/mL) and 5 mL of AgNO3 (4 mg/mL) were slowly added
to the above ddH2O solution. After stirring for 10 min
at room temperature, 10 mL of NaOH solution (pH = 12) was slowly added
into the ddH2O solution and stirred for 12 h at 37 °C.
Finally, the solution was centrifuged to remove the unreacted sediments
from the ddH2O and alcohol. After drying in an oven at
a temperature of 65 °C, the final Bi-Ag@PVP NPs were obtained.
Characterization
The morphologies
and particle sizes of the pan class="Chemical">Bi-Ag@pan class="Chemical">PVP and Bi@PVP NPs were observed and
measured by transmission electron microscopy (TEM). Scanning electron
microscopy (SEM) was also employed to observe the morphologies of
the Bi-Ag@PVP NPs. The compositions of the Bi-Ag@PVP NPs were determined
by energy-dispersive spectroscopy (EDS) during the TEM, including
mapping analysis. Fourier transform infrared spectroscopy (FTIR) was
utilized to evaluate the surface properties of the products. The phase
features of the Bi-Ag@PVP and Bi@PVP NPs were investigated by powder
X-ray diffraction (XRD). The optical absorption spectra of the Bi-Ag@PVP
NPs and Bi@PVP NPs were obtained using an ultraviolet spectrophotometer
(South East Chemicals & Instruments Ltd, China). Finally, dynamic
light scattering (DLS) was used to analyze the size distribution of
Bi-Ag@PVP NPs in phosphate-buffered saline (PBS, pH = 7.4), acidic
PBS (pH = 6.8), serum, and 1640 medium.
Animal
Model
Female BALB/cpan class="Species">nude mice
were purchased from the Xiamen University Laboratory Animal Center
(Xiamen, China). HepG2 cells (1.0 × 107/mL) were subcutaneously
injected into the right hind legs of the mice to induce tumor formation.
All animal experiments were performed according to the protocol approved
by the Animal Care and Use Committee of Xiamen University.
Photothermal Effect of Bi-Ag@PVP NPs In Vitro
and In Vivo
Various concentrations (0.5, 1, and 2 mg/mL)
of n class="Chemical">n class="Chemical">Bi-Ag@ne">pan>n class="Chemical">PVP and Bi@PVP NP suspensions and PBS solution were prepared
and irradiated under an 808 nm laser (2 W/cm2) for 5 min.
The infrared thermal imager (Joint Vision Technology Company Ltd,
Ax5, China) was used to record the temperature changes every 10 s.
Then, the photostability of the Bi-Ag@PVP NPs was studied. First,
500 μg/mL of the Bi-Ag@PVP NP suspension was irradiated with
an 808 nm laser (2 W/cm2). When the temperature reached
the peak, the power was turned off and then the suspension was naturally
cooled for three cycles. The temperature changes were recorded with
the infrared thermal imager, as described above. To study the photothermal
effect in vivo, the Bi-Ag@PVP and Bi@PVP NP suspensions (1 mg/mL,
100 μL) and the PBS solution were intratumorally injected. After
anesthesia, the mice were irradiated with an 808 nm laser (2 W/cm2), and the corresponding temperature changes and infrared
thermal images were recorded and captured.
Intracellular
ROS Detection
The pan class="CellLine">HepG2
cells were cocultured with or without 400 μg/mL of the Bi-Ag@PVP
NPs for 24 h. The HepG2 cells were cultured without Bi-Ag@PVP NPs
as the control group. The remaining groups were irradiated with or
without NIR (2 W/cm2, 5 min). A 2′-7′dichlorofluorescin
diacetate (DCFH-DA) probe (Yeasen, China) was subsequently diluted
with a serum-free medium (1:1000) and cocultured with the cells for
30 min. The HepG2 cells were then fixed with paraformaldehyde fixative
for 10 min, and the nuclei were stained with Hoechst (Yeasen, China).
Finally, the cells were observed via confocal laser scanning microscopy
(CLSM, Nikon A1R, Japan).
Cytotoxicity Evaluation
The pan class="Disease">cytotoxicity
of the Bi-Ag@PVP NPs was evaluated by a CCK-8 assay. Various concentrations
of the Bi-Ag@PVP NPs (0, 25, 50, 100, 200, 400, and 800 μg/mL)
were added to the HepG2 cells and cocultured for 12 or 24 h. Subsequently,
the CCK-8 Kit (Yeasen, China) was used to detect the cell viability
according to the protocol provided by the manufacturer. The above
experiment was repeated in triplicate.
In Vitro
Tumor Cell Ablation
To study
the pan class="Disease">tumor ablation ability of the Bi-Ag@PVP NPs in vitro, the Live/Dead
staining assay and CCK-8 assay were performed to detect the tumor
cell ablation effect of the Bi-Ag@PVP NPs. The Bi-Ag@PVP NPs with
concentrations ranging from 0 to 800 μg/mL were added to the
cells and irradiated with an 808 nm laser (2 W/cm2, 5 min),
after which they were cultured for additional 12 h. Subsequently,
the CCK-8 assay was performed, as mentioned above. Finally, the relative
cell viabilities at different concentrations were calculated. The
Live/Dead staining assay was further performed to evaluate the antitumor
effect of the Bi-Ag@PVP NPs in vitro. In detail, the HepG2 cells were
cocultured with or without 400 μg/mL of the Bi-Ag@PVP NPs. After
the HepG2 cells were treated with or without an 808 nm laser (2 W/cm2, 5 min), the cells were stained with Calcein-AM and propidium
iodide (PI) for 30 min. The cells were then observed via CLSM. The
above experiments were also repeated in triplicate.
Cellular Uptake
First, the pan class="Chemical">Bi-Ag@ne">pan class="Chemical">PVP
NPs were labeled with rhodamine through the NHS/EDC reaction. Then,
the HepG2 cells were cocultured with the rhodamine-labeled Bi-Ag@PVP
NPs (400 μg/mL) for different times (0.5, 1, 3, and 6 h) at
37 °C. The cells were then washed with PBS three times and fixed
with paraformaldehyde fixative. The nuclei were stained with Hoechst
solution at room temperature for 10 min. Finally, the fluorescence
intensity of the cells was observed by CLSM.
Apoptosis
Analysis
The pan class="CellLine">HepG2 cells
were cultured with Bi-Ag@PVP NPs at different concentrations (0, 100,
200, and 400 μg/mL) overnight, and then the cells were irradiated
with or without an 808 nm laser (2 W/cm2) for 5 min. The
cells were then collected and stained using the Annexin V-FITC/PI
Apoptosis Detection Kit (Vazyme, China) according to the manufacturer’s
protocol. The apoptosis rate of the HepG2 cells was detected using
a flow cytometer (Beckman, United States).
Mitochondrial
Function Evaluation
The JC-1 mitochondrial membrane potential
(MMP) assay was used to
detect whether the n class="Gene">pan class="Chemical">Bi-Ag@pan class="Chemical">PVP NPs could damage the mitochondria after
808 nm laser irradiation. HepG2 cells were cocultured with or without
Bi-Ag@PVP NPs for 6 h. The HepG2 cells were cultured without Bi-Ag@PVP
NPs as a control group. The remaining groups were irradiated with
or without 808 nm irradiation (2 W/cm2, 5 min) and then
incubated for another 6 h. Finally, the cells were labeled using the
JC-1 kit (MedChemExpress, China) according to the protocol provided
by the manufacturer, and the fluorescence intensity of the cells was
observed by CLSM.
Western Blot Assay
The pan class="CellLine">HepG2 cells
with different treatments (1, without Bi-Ag@PVP NPs or 808 nm laser;
2, with only 808 nm laser for 5 min; 3, with only Bi-Ag@PVP NPs; 4,
100 μg/mL Bi-Ag@PVP NPs + 808 nm laser; 5, 200 μg/mL Bi-Ag@PVP
NPs + 808 nm laser; and 6, 400 μg/mL Bi-Ag@PVP NPs + 808 nm
laser) were collected. The proteins were completely extracted, and
their concentrations was determined using a bicinchoninic acid (BCA)
protein assay kit (Yeasen, China). After electrophoresis and being
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore,
Germany), 5% skimmed milk was used to block the nonspecific binding
sites. Subsequently, the membranes were incubated with HSP 70, Bcl-2,
caspase-3, and caspase-8 (1:500, ProteinTech, rabbit) at 4 °C
while being shaken slowly overnight, after which they were washed
with TBST three times and then incubated with secondary antibodies
(antirabbit, ProteinTech) for 2 h. Subsequently, the PVDF membranes
containing the protein of interest were analyzed using an automatic
chemiluminescence imaging analysis system (Tanon, China).
In Vivo Tumor Ablation and Histological Assay
To study
the in vivo pan class="Disease">tumor ablation effect of Bi-Ag@PVP NPs, 16
HepG2-bearing nude mice were randomly divided into four groups for
different experimental purposes: (a) control, (b) 808 nm laser irradiation
(2 W/cm2, 5 min), (c) Bi-Ag@PVP NPs (400 μg/mL),
and (d) Bi-Ag@PVP NPs + 808 nm laser irradiation. Groups (c) and (d)
were injected with Bi-Ag@PVP NPs, while the other two groups were
injected with an equivalent amount of PBS solution. After groups (b)
and (d) were irradiated under an 808 nm laser (2 W/cm2)
for 5 min, the tumor volume and body weight of each group after treatment
were calculated and recorded over 12 days. After 12 days, all the
mice were sacrificed and dissected to extract the major organs (heart,
liver, spleen, lungs, kidneys, and brain). Subsequently, hematoxylin
and eosin (H&E) staining was performed following a previously
reported procedure.[27]
CT Performance of Bi-Ag@PVP NPs
To study the in vitro
CT performance of the n class="Gene">pan class="Chemical">Bi-Ag@pan class="Chemical">PVP NPs, different
concentrations of Bi-Ag@PVP NP and Iohexol solutions (0, 0.5, 1, 2,
5, 10, and 20 mg/mL) were prepared and transferred into 300-μL
Eppendorf (EP) tubes. The images and CT values were captured and recorded
using an X-ray CT machine (Siemense Inveon PET/CT, Germany) operated
at 80 kV and 50 μA. The in vivo CT scans were performed as follows.
The HepG2-bearing mice were intraperitoneally anesthetized, and the
corresponding CT images before and after the Bi-Ag@PVP NPs (100 μL,
1 mg/mL) were intratumorally administered and collected.
PA Performance of Bi-Ag@PVP NPs
The in vitro n class="Gene">PAn> imaging
was performed as follows. Different concentrations
of Bi-Ag@PVP NP suspensions (0, 12.5, 25, 50, and 100 μg/mL)
were prepared and transferred into 300 μL EP tubes. The PA images
were then captured using an ultrasonic PA multimode imaging system
(FUJIFILM VisualSonics, Japan). To study the in vivo PA performances
of the Bi-Ag@PVP NPs, the mice were intraperitoneally anesthetized
and the corresponding preinjection and postinjection PA images with
the Bi-Ag@PVP NP suspension (100 μL, 200 μg/mL) were obtained.
Antibacterial Capacity
The antibacterial
properties of the pan class="Chemical">Bi-Ag@pan class="Chemical">PVP NPs were explored by a coculture of the
Bi-Ag@PVP NPs with E. coli and 808
nm laser irradiation of the NPs to observe the effect on the bacterial
growth. Briefly, the bacterial suspensions with concentrations of
107 cfu/mL were cocultured with the Bi-Ag@PVP NPs (400
μg/mL), and the bacterial suspensions containing different concentrations
of NPs (100, 200, and 400 μg/mL) were irradiated with an 808
nm laser (2 W/cm2, 5 min). The bacterial suspensions without
NPs or with only laser irradiation were used as the controls. All
the suspensions were incubated at 37 °C for 24 h, and then the
bacterial suspensions were measured at 600 nm to obtain the corresponding
optical density values. The bacterial suspensions were diluted and
placed on Luria BrothAgar to observe the formation of bacterial colonies.
Finally, SEM was used to observe the morphology of the bacteria after
irradiation, as previously reported.[28]
Statistical Analysis
All the statistical
significance values were analyzed via Student’s t-test and one-way analysis of variance using the Origin (version
9.0) software. All quantitative results were expressed as mean ±
standard deviation, and *P < 0.05 was considered
to be statistically significant. The CT and n class="Gene">pan class="Gene">PA signal intensities
were quantified by the software that came with the instrune">pan>n class="Species">ments.
Results and Discussion
Fabrication
and Physical Characteristics of
Bi-Ag@PVP NPs
The fabrication process of the n class="Chemical">n class="Chemical">Bi-Ag@ne">pan>n class="Chemical">PVP NPs
is shown in Scheme . First, the Bi@PVP NPs were prepared via a facile solvothermal method,
and then the BSA reduced AgNO3 into Ag+. Finally,
the Ag+ was adsorbed on the surface of the Bi@PVP NPs by
electrostatic adsorption to form Bi-Ag@PVP NPs. The TEM images (Figure A) reveal the morphologies
and particle sizes of the Bi@PVP and Bi-Ag@PVP NPs. The Bi-Ag@PVP
NPs exhibited nanoheterostructures, and compared with the Bi NPs,
the Bi-Ag@PVP NPs had a slightly larger particle size (272.2 ±
17.11 nm) than the Bi@PVP NPs (250.0 ± 16.36 nm). The SEM image
of the Bi-Ag@PVP NPs shows their nanoheterostructures (Figure B). The EDS (Figure C) spectra show that the samples
contained C, Bi, N, Ag, and S. Based on the TEM, EDS, and SEM results,
we concluded that the Bi-Ag@PVP NPs were successfully prepared. Figure D shows the XRD patterns
of the Bi@PVP and Bi-Ag@PVP NPs, and all peaks of the Bi@PVP NPs were
well matched with the bismuth standard card (PDF#85-1329). The XRD
pattern of Bi-Ag@PVP NPs is shown by a green line. All the peaks well
matched with the Bi@PVP NPs, except for the characteristic peak of
the blue line frame, which was consistent with the silver standard
card (PDF#89-3722). This further indicated that the Bi-Ag@PVP NPs
were successfully synthesized. Previous studies demonstrated that
PVP could improve the biocompatibility of NPs.[29−31] Thus, the PVP
was coated on the surfaces of the Bi@PVP NPs, improving the stability
and biocompatibility of the final products. FTIR spectra were employed
to verify the surface properties of the Bi and Bi-Ag NPs. Figure E shows that both
the Bi and the Bi-Ag NPs possessed C=O and C–N groups with
strong absorption peaks at 1610 and 1380 cm–1, respectively,
which are the characteristic groups of PVP, indicating the presence
of PVP on the surfaces of the NPs.[32]Figure F shows that both
the Bi@PVP and Bi-Ag@PVP NPs exhibited a broad absorption peak in
the ultraviolet (UV)–visible (vis)–NIR spectrum, suggesting
that the as-prepared Bi-Ag@PVP NPs could have potential photothermal
effects. In addition, the absorption wavelength of the Bi-Ag@PVP NPs
was similar to that of the Bi@PVP NPs. However, it is important to
point out that there were subtle differences in their absorption spectra,
which may have been due to the Ag of the Bi-Ag@PVP NPs. As is well
known, a relatively uniform particle size distribution is a prerequisite
for NPs in biological applications. Thus, DLS was used to analyze
the size distributions of the Bi-Ag@PVP NPs in different solutions. Figure G shows that the
Bi-Ag@PVP NPs had relatively concentrated particle size distributions
in PBS (pH = 7.4), acidic PBS (pH = 6.8), serum, and 1640 medium,
indicating that the Bi-Ag@PVP NPs had good stability in the different
solutions. Thus, they are suitable for biological applications.
Scheme 1
Schematic Diagram of the Synthesis Process and the Corresponding
Functions of the Bi-Ag@PVP NPs
Figure 1
(A) TEM
images of Bi and Bi-Ag@PVP NPs. (B) SEM image of Bi-Ag@PVP
NPs. (C) Dark-field TEM image of Bi-Ag@PVP NPs and the corresponding
TEM elemental mapping images of C, Bi, N, Ag, and S. (D) XRD patterns
and (E) FTIR spectra of Bi@PVP and Bi-Ag@PVP NPs. (F) UV–NIR
absorption spectra of water (green), Bi@PVP NPs (blue), and Bi-Ag@PVP
NPs (red). (G) DLS histograms of Bi-Ag@PVP NPs in PBS (pH = 7.4),
PBS (pH = 6.8), serum, and 1640 medium.
(A) TEM
images of Bi and pan class="Chemical">Bi-Ag@pan class="Chemical">PVP NPs. (B) SEM image of Bi-Ag@PVP
NPs. (C) Dark-field TEM image of Bi-Ag@PVP NPs and the corresponding
TEM elemental mapping images of C, Bi, N, Ag, and S. (D) XRD patterns
and (E) FTIR spectra of Bi@PVP and Bi-Ag@PVP NPs. (F) UV–NIR
absorption spectra of water (green), Bi@PVP NPs (blue), and Bi-Ag@PVP
NPs (red). (G) DLS histograms of Bi-Ag@PVP NPs in PBS (pH = 7.4),
PBS (pH = 6.8), serum, and 1640 medium.
Photothermal Performances of Bi@PVP and Bi-Ag@PVP
NPs
The photothermal performances of Bi@pan class="Chemical">PVP and ne">pan class="Chemical">Bi-Ag@PVP
NPs were measured by employing NIR irradiation (808 nm, 2 W/cm2). As shown in Figure B, the temperatures of the Bi-Ag@PVP suspensions of various
concentrations (0.5, 1, and 2 mg/mL) increased rapidly from 0 to 120
s, and then the temperatures rose slowly from 120 to 300 s. Compared
with the solution temperatures before irradiation, the temperatures
of the Bi-Ag@PVP NP suspensions with concentrations of 0.5, 1, and
2 mg/mL increased by 30.6, 36.0, and 42.3 °C after irradiation,
respectively. Meanwhile, the PBS group exhibited negligible temperature
elevations (ΔT). The infrared thermal images
for the Bi-Ag@PVP NP suspensions (0.5, 1, and 2 mg/mL) and PBS at
different times were captured using a thermal imager (Figure A). Figure C,D shows that the ΔT of the Bi@PVP NP suspensions (0.5, 1, and 2 mg/mL) also increased
and the corresponding temperatures at different intervals were also
captured by the thermal imager. Compared with the Bi@PVP NP suspension
at the same concentration, the Bi-Ag@PVP NP suspension exhibited more
violent temperature changes. The ΔT values
of the former were 20.2, 24.8, and 29.4 °C, respectively, lower
than those of Bi-Ag@PVP NPs. This phenomenon may have been related
to the enhanced surface plasmon resonance derived from Ag.
Figure 2
(A) Infrared
thermal images of the Bi-Ag@PVP NPs at different times
and (B) the fitted curves. (C) Photothermal heating curves of the
Bi@PVP NPs and (D) the corresponding infrared thermal images. (E and
F) Infrared thermal images and the corresponding temperature–time
curves of the Bi@PVP (purple) and Bi-Ag@PVP (red) NPs in HepG2-bearing
mice. (G) Heating/cooling cycle curve of the Bi-Ag@PVP NPs.
(A) Infrared
thermal images of the pan class="Chemical">Bi-Ag@ne">pan class="Chemical">PVP NPs at different times
and (B) the fitted curves. (C) Photothermal heating curves of the
Bi@PVP NPs and (D) the corresponding infrared thermal images. (E and
F) Infrared thermal images and the corresponding temperature–time
curves of the Bi@PVP (purple) and Bi-Ag@PVP (red) NPs in HepG2-bearing
mice. (G) Heating/cooling cycle curve of the Bi-Ag@PVP NPs.
Encouraged by the excellent photothermal results
of the n class="Chemical">n class="Chemical">Bi-Ag@ne">pan>n class="Chemical">PVP
NPs in vitro, we then compared the photothermal effects of the Bi-Ag@PVP
NPs with the Bi@PVP NPs in HepG2-bearing mice. Figure E,F shows that after intratumoral injection
of the Bi-Ag@PVP and Bi@PVP NPs at the same concentration (100 μL,
1 mg/mL) and 808 nm laser irradiation (2 W/cm2, 5 min),
the temperature at the tumor sites after the administration of the
Bi-Ag@PVP and Bi@PVP NP solutions increased by 19.7 and 11.4 °C,
respectively, corresponding to the final temperatures of 52.4 and
45.6 °C, respectively. However, the tumor site temperature of
the mice administered with PBS did not increase significantly. The
in vivo photothermal performance proved that the Bi-Ag@PVP NPs could
effectively convert the light into heat in vivo. Figure G shows that after rapid heating/cooling
for three cycles, there was no apparent attenuation of the temperature–time
curve, demonstrating that the Bi-Ag@PVP NPs possessed great photostability
properties. According to previous studies, when the cellular temperature
is higher than 39 °C, protein denaturation begins.[33,34] When the cellular temperature exceeds 41 °C, the cells will
be inactivated for several hours, and when the temperature is greater
than 48 °C for extended periods (4–6 min), the cell inactivation
will become irreversible.[35,36] Thus, the above results
showed that the Bi-Ag@PVP NPs could serve as a potential candidate
for PTA. They possessed good photostability and could exert an excellent
PTT effect.
Intracellular ROS Generation
To monitor
whether the pan class="Chemical">Bi-Ag@ne">pan class="Chemical">PVP NPs can induce the formation of intracellular
ROS in HepG2 cells, a DCFH-DA probe was used to detect the intracellular
ROS production. Nonfluorescent DCFH-DA could enter a cell freely,
and the intracellular esterase hydrolyzed the DCFH-DA into DCFH after
penetrating the cell membrane. The DCFH then accumulated in the cells,
and the intracellular ROS oxidized the DCFH to fluorescent DCF, showing
green fluorescence, which was evident under CLSM. As shown in Figure , intense green fluorescence
was detected after the Bi-Ag@PVP NPs were irradiated with the 808
nm laser (2 W/cm2) for 5 min, indicating the intracellular
generation of ROS while the other three groups showed negligible fluorescence
under CLSM. Thus, we concluded that after irradiation with the 808
nm laser, the Bi-Ag@PVP NPs could induce intracellular ROS generation,
which indicated that the Bi-Ag@PVP NPs possessed PDT properties.
Figure 3
Fluorescence
images of intracellular ROS in HepG2 cells. Strong
green fluorescence was observed in Bi-Ag@PVP NPs + 808 nm laser-irradiated
sample (scale bar: 100 μm).
Fluorescence
images of intracellular pan class="Chemical">ROS in pan class="CellLine">HepG2 cells. Strong
green fluorescence was observed in Bi-Ag@PVP NPs + 808 nm laser-irradiated
sample (scale bar: 100 μm).
Biosafety and Tumor Destruction In Vitro
High biocomn class="Gene">patibility and n class="Disease">low cytotoxicity are indispensable for
the biological application of NPs.[37,38] Before evaluating
biosafety and pan class="Disease">tumor destruction effects in vitro, the internalization
behavior of Bi-Ag@PVP NPs was studied. Rhodamine-labeled Bi-Ag@PVP
NPs were cocultured with HepG2 cells for different time periods (0.5,
1, 3, and 6 h). Figure A shows that a time-dependent enhanced red fluorescence occurred,
indicating that the Bi-Ag@PVP NPs could be effectively internalized
into HepG2 cells in a relatively short time. After studying the cellular
uptake process of NPs, we then studied the cytocompatibility of Bi-Ag@PVP
NPs, Figure B reveals
the cell viability of HepG2 cells incubated with various concentrations
of NPs for different times. The experimental groups of HepG2 cells
all had high cell viabilities from 81.4% to 98.4%. Furthermore, when
the Bi-Ag@PVP NP concentration reached 800 μg/mL and cocultured
with HepG2 cells for 24 h, the HepG2 cells retained high cell viability
(81.4%). These results indicated that the Bi-Ag@PVP NPs had favorable
biocompatibility in vitro. Next, the tumor ablation effect in vitro
was studied through CCK-8 and Live/Dead staining. The HepG2 cells
were treated with different concentrations of Bi-Ag@PVP suspensions
and irradiated under an 808 nm laser (2 W/cm2) for 5 min. Figure C shows that as the
concentrations of Bi-Ag@PVP NP suspensions increased, the cell viability
decreased significantly, and the cell survival rate decreased by only
about 10% when the concentration of the Bi-Ag@PVP NP suspension reached
800 μg/mL. This result indicated that the Bi-Ag@PVP NPs could
exhibit synergistic PDT and PTT to exert excellent tumor ablation
effects in vitro. Moreover, Live/Dead staining was also performed
to prove the in vitro tumor destruction of Bi-Ag@PVP NPs. Figure D shows that compared
with the control group, there was little red fluorescence observed
in the NIR-only group and the group with only the sample. This indicated
that no apparent cell death occurred in the above two groups, which
was consistent with the CCK-8 results. After the Bi-Ag@PVP NPs were
irradiated with the 808 nm laser (2 W/cm2, 5 min), strong
red fluorescence was observed. However, negligible green fluorescence
was detected, which indicated that the HepG2 cells were almost completely
ablated. The above-mentioned results indicated that the Bi-Ag@PVP
NPs had low cytotoxicity and great in vitro tumor ablation effects
through synergistic PDT and PTT.
Figure 4
(A) CLSM images of HepG2 cells cocultured
with rhodamine-labeled
Bi-Ag@PVP NPs at different times (0.5, 1, 3, and 6 h) (scalebar: 20
μm). CCK-8 assay results for cell viability after (B) different
treatments in the dark and (C) under 808 nm laser (2 W/cm2) for 5 min. (D) CLSM images of HepG2 cells after different treatments
and staining with Calcein-AM and PI (scale bar: 100 μm). Note: P < 0.05 was considered a significant difference; *P < 0.05, **P < 0.01, ***P < 0.001.
(A) CLSM images of pan class="CellLine">HepG2 cells cocultured
with rhodamine-labeled
Bi-Ag@PVP NPs at different times (0.5, 1, 3, and 6 h) (scalebar: 20
μm). CCK-8 assay results for cell viability after (B) different
treatments in the dark and (C) under 808 nm laser (2 W/cm2) for 5 min. (D) CLSM images of HepG2 cells after different treatments
and staining with Calcein-AM and PI (scale bar: 100 μm). Note: P < 0.05 was considered a significant difference; *P < 0.05, **P < 0.01, ***P < 0.001.
Bi-Ag@PVP-NP-Induced
Apoptosis and Its Mechanisms
Encouraged by the above results,
we next explored the effect of
the pan class="Chemical">Bi-Ag@pan class="Chemical">PVP NPs on HepG2 cell apoptosis and their mechanisms. Figure A shows that the
Bi-Ag@PVP NPs could efficiently induce cell apoptosis, and the rate
of apoptosis gradually increased (from 42.47% to 82.1%) as the concentration
of the Bi-Ag@PVP NPs increased. However, the apoptosis induced by
Bi-Ag@PVP NPs was mainly early apoptosis. We subsequently studied
the mechanism of the Bi-Ag@PVP-NP-induced cell apoptosis. It is well
known that mitochondrial dysfunction represents the early stages of
apoptosis.[39,40] Thus, the JC-1 MMP assay was
used to detect whether the mitochondria were functioning normally.
JC-1 aggregates could be detected in the form of red fluorescence,
indicating that the mitochondria functioned well. When the MMP (ΔΨm) changed (ΔΨm is high in
healthy cells and low in unhealthy cells), the JC-1 aggregates transformed
into JC-1 monomers, which appeared as green fluorescence. As shown
in Figure C, only
slight green fluorescence was observed in different treatment groups
(control, only 808 nm laser irradiation, and only Bi-Ag@PVP NPs).
However, a large amount of green fluorescence was observed in the
treatment group with the Bi-Ag@PVP NPs under 808 nm irradiation, indicating
that the mitochondria were dysfunctional. As mentioned above, mitochondrial
dysfunction can cause early cell apoptosis; hence, the mechanism through
which the Bi-Ag@PVP NPs induced cell apoptosis may be attributed to
the pathway of mitochondrial dysfunction. Two molecules are mainly
responsible for regulating cell apoptosis: the caspase family and
the Bcl-2 family.[41,42] Both families are related to
the mitochondrial apoptosis pathway. Thus, we tested the expression
of the related proteins in HepG2 cells under different treatment conditions. Figure B shows that the
decrease in the antiapoptotic Bcl-2 protein was detected, and the
amount of protein expression gradually decreased with an increase
in the Bi-Ag@PVP NP concentration. Meanwhile, the expression of caspase-3
and caspase-8 also gradually increased with an increase in the Bi-Ag@PVP
concentration. Furthermore, the expression of HSP 70 was detected,
which is synthesized by a cell to protect itself from hyperthermia
or oxidative stress.[43] After the Bi-Ag@PVP
NPs were irradiated with the 808 nm laser, the expression of HSP 70
significantly increased, indicating that the HepG2 cells underwent
thermal damage, which may have also caused mitochondrial dysfunction.
The corresponding statistical analyses of the protein expression are
given in Figure D.
These results demonstrated that Bi-Ag@PVP NPs could induce HepG2 cells
apoptosis, which may have occurred through the mitochondrial apoptosis
pathway.
Figure 5
(A) Cell apoptosis rate after different treatments (a: control,
b: laser only, c: Bi-Ag@PVP NPs alone, d: Bi-Ag@PVP NPs (100 μg/mL)
+ laser, e: Bi-Ag@PVP NPs (200 μg/mL) + laser, and f: Bi-Ag@PVP
NPs (400 μg/mL) + laser). (B) Caspase-8, caspase-3, Bcl-2, and
HSP 70 protein levels in HepG2 cells after different treatments (a–f
have the same meanings as in (A)). (C) CLSM images of HepG2 cells
after different treatments and staining by the JC-1 kit. The blue
fluorescence corresponds to 4′,6-diamidino-2-phenylindole (DAPI),
the red fluorescence corresponds to JC-1 aggregates, and the green
fluorescence corresponds to JC-1 monomers (scalebar: 20 μm).
(D) Statistical analysis of protein expression (caspase-8, caspase-3,
Bcl-2, and HSP 70).
(A) Cell apoptosis rate after different treatpan class="Species">ments (a: control,
b: laser only, c: Bi-Ag@PVP NPs alone, d: Bi-Ag@PVP NPs (100 μg/mL)
+ laser, e: Bi-Ag@PVP NPs (200 μg/mL) + laser, and f: Bi-Ag@PVP
NPs (400 μg/mL) + laser). (B) Caspase-8, caspase-3, Bcl-2, and
HSP 70 protein levels in HepG2 cells after different treatments (a–f
have the same meanings as in (A)). (C) CLSM images of HepG2 cells
after different treatments and staining by the JC-1 kit. The blue
fluorescence corresponds to 4′,6-diamidino-2-phenylindole (DAPI),
the red fluorescence corresponds to JC-1 aggregates, and the green
fluorescence corresponds to JC-1 monomers (scalebar: 20 μm).
(D) Statistical analysis of protein expression (caspase-8, caspase-3,
Bcl-2, and HSP 70).
In Vivo
Tumor Ablation and Biocompatibility
The in vivo n class="Disease">tumorn> ablation
effect of the Bi-Ag@PVP NPs wase determined
by intratumorally injecting the Bi-Ag@PVP NP suspension (100 μL,
400 μg/mL) into HepG2-bearing mice followed by NIR irradiation
(808 nm, 2 W/cm2, 5 min). Figure B,C reveals that due to the high malignancy
of hepatocellular cancer, the tumor volume without any treatment rapidly
increased. The NP and 808 nm laser irradiation-alone groups could
not exert PDT/PTT effects; thus, the tumor sizes increased rapidly.
Surprisingly, the Bi-Ag@PVP NPs (100 μL, 400 μg/mL) +
808 nm irradiation group tumors were completely ablated (Figure B,C), demonstrating
that the Bi-Ag@PVP-based PDT/PTT had great antitumor effects in vivo.
Furthermore, the body weights (Figure A) in all groups slightly increased, and there was
no significant difference, suggesting that the NIR and NPs have no
significant influence on the health of the mice. After treatment,
histological studies were performed to determine the biocompatibility
of the Bi-Ag@PVP NPs. As shown in Figure D, there were no apparent histological changes
in any group. More importantly, there was no significant damage to
metabolic organs, indicating the outstanding biocompatibility of the
Bi-Ag@PVP NPs. These results demonstrated that the Bi-Ag@PVP NPs could
achieve PDT/PTT synergy to exert outstanding antitumor effects, while
causing no evident damage to normal organs.
Figure 6
(A) Relative body weights
after different treatments. (B) Images
of HepG2-bearing mice after 12 days of treatment. (C) Tumor volume
changes after 12 days of treatment. (D) H&E staining of major
organs in different treatments groups (scalebar: 200 μm).
(A) Relative body weights
after different treatpan class="Species">ments. (B) Images
of HepG2-bearing mice after 12 days of treatment. (C) Tumor volume
changes after 12 days of treatment. (D) H&E staining of major
organs in different treatments groups (scalebar: 200 μm).
CT Performance of Bi-Ag@PVP
NPs In Vitro and
In Vivo
The ideal nanotheranostic platform should possess
a multimodality of imaging and therapy. In particular, during the
application of PTAs for treatn class="Gene">pan class="Species">ment, accurate sclass="Chemical">ne">pan>tiotemporal change
monitoring is required, which can guide the therapeutic process, monitoring
the efficacy, avoiding damage to the surrounding tissue, and reducing
the associated side effects.[44] Due to the
excellent X-ray attenuation coefficient of Bi,[45−47] the Bi-Ag@PVP
NPs were expected to be qualified for CT imaging. It is well known
that as one of the commonly used noninvasive methods, CT has the ability
to produce internal tissue and organ cross-sectional images with high
resolution and low cost.[48−51] Thus, it is an essential way to diagnose various
clinical diseases, including tumors. Herein, we studied the CT performance
of the Bi-Ag@PVP NPs. Figure A shows the corresponding CT images of the Bi-Ag@PVP NPs and
Iohexol. As the concentration of the suspension increased, the gray
level of the image gradually changed from a black shade to a white
shade. However, at the same concentration, the Bi-Ag@PVP NPs produced
a brighter shade than Iohexol because the X-ray attenuation coefficient
of Bi is higher than that of I (the value for Bi is 5.74 cm2 kg–1 and that for I is 1.94 cm2 kg–1, at 100 keV).[52]Figure B shows the relationship
between the CT values and the concentration of the Bi-Ag@PVP NPs and
Iohexol. The R2 values of the fitted curves
were larger than 0.99, indicating the great fit between the concentration
and CT values. Meanwhile, the slope of the Bi-Ag@PVP NPs was 52.39,
which was much higher than that of Iohexol (slope = 29.67). These
results indicate that compared with Iohexol, the Bi-Ag@PVP NPs produced
a better CT contrast effect in vitro. Encouraged by the above results,
we then evaluated the CT performance of Bi-Ag@PVP NPs in vivo. The
HepG2-bearing mice were intraperitoneally anesthetized. Subsequently,
the Bi-Ag@PVP suspension (1 mg/kg, 100 μL) was injected intratumorally
into the HepG2-bearing mice. The images of the tumor sites pre and
postinjection of the Bi-Ag@PVP NP suspension are shown in Figure C. There was no significant
CT signal intensity at the tumor site before injection. After the
administration of the Bi-Ag@PVP NPs, the CT signal at the tumor site
was greatly enhanced (shown by the red circle), and the CT signal
intensities before and after injection are given in Figure D. The above results indicate
that Bi-Ag@PVP NPs can be a promising candidate for in vitro and in
vivo CT contrast agents.
Figure 7
(A) X-ray absorption capacity of Bi-Ag@PVP and
Iohexol and (B)
signal-concentration fitting curves. (C) In vivo CT imaging ability
of Bi-Ag@PVP NPs (the tumor site is highlighted by the red circle)
and (D) the corresponding CT signal intensity.
(A) X-ray absorption capacity of pan class="Chemical">Bi-Ag@pan class="Chemical">PVP and
Iohexol and (B)
signal-concentration fitting curves. (C) In vivo CT imaging ability
of Bi-Ag@PVP NPs (the tumor site is highlighted by the red circle)
and (D) the corresponding CT signal intensity.
PA Performance of Bi-Ag@PVP NPs In Vitro and
In Vivo
As another widely used and noninvasive biomedical
method, n class="Gene">pan class="Gene">PA imaging utilizes lasers to acoustically visualize biological
tissue, providing relatively deep imaging penetration and good sclass="Chemical">ne">pan>tial
resolution.[45,53,54]Figure A reveals
that as the concentrations of the Bi-Ag@PVP NP suspensions gradually
increased, greater red signal intensity was detected under 808 nm
laser irradiation, and the quantitative analysis of the PA intensity
is shown in Figure B, suggesting the great in vitro PA imaging capacity of the Bi-Ag@PVP
NPs.
Figure 8
(A) PA images and (B) quantitative diagram of the PA intensity
with different concentrations (0, 12.5, 25, 50, and 100 μg/mL).
(C) PA images of the tumor site before and after intratumorally administering
the Bi-Ag@PVP NP suspension (100 μL, 200 μg/mL). (D) Quantitative
PA intensity of the tumor site before and after administering the
Bi-Ag@PVP NP suspension (100 μL, 200 μg/mL).
(A) pan class="Gene">PA images and (B) quantitative diagram of the PA intensity
with different concentrations (0, 12.5, 25, 50, and 100 μg/mL).
(C) PA images of the tumor site before and after intratumorally administering
the Bi-Ag@PVP NP suspension (100 μL, 200 μg/mL). (D) Quantitative
PA intensity of the tumor site before and after administering the
Bi-Ag@PVP NP suspension (100 μL, 200 μg/mL).
The pan class="Gene">PA imaging ability of the Bi-Ag@PVP NPs was further studied
in vivo. Figure C
shows that slight red PA signals were observed in the tumor site before
administration, which may have been caused by tumor blood.[44] In contrast, the PA signal was remarkably increased
after the in situ administration of the Bi-Ag@PVP NP suspensions (100
μL, 200 μg/mL). The PA intensity after injection was approximately
4 times greater than that before injection (see Figure D). Thus, the Bi-Ag@PVP NPs are expected
to be a highly effective contrast agent for PA imaging. Based on the
CT and PA imaging performances, we concluded that Bi-Ag@PVP NPs can
be used as a highly effectively multimodal contrast agent for CT/PA
imaging-guided PDT/PTT synergistic therapy.
Antibacterial
Ability
For most n class="Disease">tumorsn>,
chemical drug-mediated chemotherapy is an effective treatment. However,
most chemical drugs can damage the immune system, leading to decreased
immune function in patients with or without defects.[55−57] Therefore, bacterial infections have become a common complication
in tumor treatment. Silver is an agent with a long history that has
been widely used for controlling infections, including Pseudomonas
aeruginosa, Staphylococcus aureus, and E. coli infections.[58,59] Recently,
with the development of nanotechnology, silver-based NPs are commonly
used to treat various infections and burn wounds due to their excellent
antibacterial properties.[60−64] Thus, we evaluated the antibacterial capacity of the Bi-Ag@PVP NPs. Figure B shows that after
coculturing with Bi-Ag@PVP NPs (400 μg/mL) for 6 h, the normalized
bacterial viability of E. coli was
reduced to 81.9%, which may have been related to the silver doping
in NPs. When the Bi-Ag@PVP NPs were illuminated with NIR (808 nm,
2 W/cm2, 5 min) and then cocultured with E. coli for 6 h, the normalized bacterial viabilities
of E. coli were 63.7%, 42.9%, and 10.2%
at concentrations of 100, 200, and 400 μg/mL, respectively. Figure A shows that compared
with the control, the number of bacterial colonies in experiment groups
were significantly reduced. The morphological changes of E. coli after treatment (Bi-Ag@PVP NPs + 808 nm laser)
were observed by SEM, and Figure C shows that compared with the control group, the E. coli was significantly damaged after treatment
and the integrity of the bacteria was destroyed (shown by the red
arrow). The above results indicate that the Bi-Ag@PVP NPs have an
outstanding antibacterial capacity, which can effectively reduce the
infection risk during cancer therapy.
Figure 9
(A) Images of E. coli colonies on
different treatment groups. (B) Normalized bacterial viability after
different treatments (1: control, 2: laser alone, 3: Bi-Ag@PVP NPs
(400 μg/mL) alone, 4: Bi-Ag@PVP NPs (100 μg/mL) + laser,
5: Bi-Ag@PVP NPs (200 μg/mL) + laser, and 6: Bi-Ag@PVP NPs (400
μg/mL) + laser). (C) SEM images of E. coli before and after treatment (Bi-Ag@PVP NPs + laser). P < 0.05 was considered to be a significant difference; **P < 0.01, ***P < 0.001.
(A) Images of pan class="Species">E. coli colonies on
different treatment groups. (B) Normalized bacterial viability after
different treatments (1: control, 2: laser alone, 3: Bi-Ag@PVP NPs
(400 μg/mL) alone, 4: Bi-Ag@PVP NPs (100 μg/mL) + laser,
5: Bi-Ag@PVP NPs (200 μg/mL) + laser, and 6: Bi-Ag@PVP NPs (400
μg/mL) + laser). (C) SEM images of E. coli before and after treatment (Bi-Ag@PVP NPs + laser). P < 0.05 was considered to be a significant difference; **P < 0.01, ***P < 0.001.
These overall results indicate that the pan class="Chemical">Bi-Ag@ne">pan class="Chemical">PVP NPs can
be used
to synergize PDT and PTT, exhibiting excellent antitumor effects,
enhancing the CT/PA imaging contrast and demonstrating great antibacterial
properties. However, the long-term biocompatibility of the Bi-Ag@PVP
NPs and the metabolic processes in vivo must be further studied. Furthermore,
due to the lack of positive tumor targeting, modification of the Bi-Ag@PVP
NPs with tumor-specific targeting antibodies (such as anti-neuropilin
antibodies)[65] or targeting peptides[66] can achieve precise tumor-targeted therapy and
real-time CT/PA monitoring, thereby reducing the occurrence of side
effects during tumor treatment in future work.
Conclusions
In summary, a smart nanotheranostic platform
pan class="Chemical">Bi-Ag@ne">pan class="Chemical">PVP NPs was
constructed and can be employed for tumor PDT/PTT, CT/PA imaging,
and antibacterial applications. The Bi-Ag@PVP NPs exhibited great
biocompatibility and better photothermal performances than Bi@PVP
NPs. Importantly, the Bi-Ag@PVP NPs can also cause tumor cells to
produce ROS, producing excellent tumor ablation abilities in vitro
and in vivo. Simultaneously, duo to the high CT and PA contrast properties
of the Bi-Ag@PVP NPs, they can achieve multimodal-guided PDT/PTT synergistic
therapy. Finally, the antibacterial properties of the Bi-Ag@PVP NPs
were also studied. The results demonstrated that Bi-Ag@PVP NPs can
effectively ablated E. coli, which
can minimize the infection risk during cancer therapy. Overall, our
research provides a novel nanotheranostic platform for cancer therapy.
Authors: Mayra Hernández-Rivera; Ish Kumar; Stephen Y Cho; Benjamin Y Cheong; Merlyn X Pulikkathara; Sakineh E Moghaddam; Kenton H Whitmire; Lon J Wilson Journal: ACS Appl Mater Interfaces Date: 2017-02-07 Impact factor: 9.229